Essence Pharmaceuticals: The company's product Carbidopa Levodopa Extended-Release Tablets has obtained a drug registration certificate.

Essence Pharmaceutical announced on November 11 that the company has received two Drug Registration Certificates for the Carbidopa Levodopa Extended-Release Tablets issued by the National Medical Products Administration. The Carbidopa Levodopa Extended-Release Tablets is the third approved enterprise in the country, and the first generic of this specification as the original product has not been registered for sale domestically. This product enriches the company's product pipeline in the treatment of Parkinson's disease and has brought more business opportunities in this specific market segment. However, the production and sales of the drug may be affected by various factors such as changes in the market environment, and there is a certain level of uncertainty in the sales situation.